Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47366
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kutlu M. | - |
dc.contributor.author | Sayın-Kutlu S. | - |
dc.contributor.author | Alp-Çavuş S. | - |
dc.contributor.author | Öztürk Ş.B. | - |
dc.contributor.author | Taşbakan M. | - |
dc.contributor.author | Özhak B. | - |
dc.contributor.author | Kaya O. | - |
dc.contributor.author | Ergin, Cagri | - |
dc.date.accessioned | 2023-01-09T21:24:10Z | - |
dc.date.available | 2023-01-09T21:24:10Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 0934-9723 | - |
dc.identifier.uri | https://doi.org/10.1007/s10096-021-04394-0 | - |
dc.identifier.uri | https://hdl.handle.net/11499/47366 | - |
dc.description.abstract | Candidemia may present as severe and life-threatening infections and is associated with a high mortality rate. This study aimed to evaluate the risk factors associated with 30-day mortality in patients with candidemia. A multi-center prospective observational study was conducted in seven university hospitals in six provinces in the western part of Turkey. Patient data were collected with a structured form between January 2018 and April 2019. In total, 425 episodes of candidemia were observed during the study period. Two hundred forty-one patients died within 30 days, and the 30-day crude mortality rate was 56.7%. Multivariable analysis found that SOFA score (OR: 1.28, CI: 1.154–1.420, p < 0.001), parenteral nutrition (OR: 3.9, CI: 1.752–8.810, p = 0.001), previous antibacterial treatment (OR: 9.32, CI: 1.634–53.744, p = 0.012), newly developed renal failure after candidemia (OR: 2.7, CI: 1.079–6.761, p = 0.034), and newly developed thrombocytopenia after candidemia (OR: 2.6, CI: 1. 057–6.439, p = 0.038) were significantly associated with 30-day mortality. Central venous catheter removal was the only factor protective against mortality (OR: 0.34, CI:0.147–0.768, p = 0.010) in multivariable analysis. Candidemia mortality is high in patients with high SOFA scores, those receiving TPN therapy, and those who previously received antibacterial therapy. Renal failure and thrombocytopenia developing after candidemia should be followed carefully in patients. Antifungal therapy and removing the central venous catheter are essential in the management of candidemia. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Science and Business Media Deutschland GmbH | en_US |
dc.relation.ispartof | European Journal of Clinical Microbiology and Infectious Diseases | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Candida | en_US |
dc.subject | Candida parapsilosis | en_US |
dc.subject | Catheter removal | en_US |
dc.subject | Mortality | en_US |
dc.subject | Risk factors | en_US |
dc.subject | amphotericin B | en_US |
dc.subject | amphotericin B lipid complex | en_US |
dc.subject | anidulafungin | en_US |
dc.subject | antibiotic agent | en_US |
dc.subject | antifungal agent | en_US |
dc.subject | caspofungin | en_US |
dc.subject | echinocandin | en_US |
dc.subject | fluconazole | en_US |
dc.subject | itraconazole | en_US |
dc.subject | micafungin | en_US |
dc.subject | posaconazole | en_US |
dc.subject | prednisolone | en_US |
dc.subject | voriconazole | en_US |
dc.subject | antifungal agent | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | antibiotic therapy | en_US |
dc.subject | antifungal susceptibility | en_US |
dc.subject | antifungal therapy | en_US |
dc.subject | Article | en_US |
dc.subject | bacteremia | en_US |
dc.subject | Candida | en_US |
dc.subject | Candida albicans | en_US |
dc.subject | Candida endocarditis | en_US |
dc.subject | Candida endophthalmitis | en_US |
dc.subject | Candida parapsilosis | en_US |
dc.subject | candidemia | en_US |
dc.subject | candidiasis | en_US |
dc.subject | catheter removal | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | controlled study | en_US |
dc.subject | corticosteroid therapy | en_US |
dc.subject | crude mortality rate | en_US |
dc.subject | data collection method | en_US |
dc.subject | drug substitution | en_US |
dc.subject | drug withdrawal | en_US |
dc.subject | female | en_US |
dc.subject | human | en_US |
dc.subject | kidney failure | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | mortality | en_US |
dc.subject | multicenter study | en_US |
dc.subject | neutropenia | en_US |
dc.subject | observational study | en_US |
dc.subject | odds ratio | en_US |
dc.subject | parenteral nutrition | en_US |
dc.subject | patient coding | en_US |
dc.subject | prospective study | en_US |
dc.subject | risk factor | en_US |
dc.subject | Sequential Organ Failure Assessment Score | en_US |
dc.subject | thrombocytopenia | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | university hospital | en_US |
dc.subject | unspecified side effect | en_US |
dc.subject | candidemia | en_US |
dc.subject | clinical trial | en_US |
dc.subject | microbiology | en_US |
dc.subject | retrospective study | en_US |
dc.subject | turkey (bird) | en_US |
dc.subject | Antifungal Agents | en_US |
dc.subject | Candida | en_US |
dc.subject | Candidemia | en_US |
dc.subject | Humans | en_US |
dc.subject | Prospective Studies | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Risk Factors | en_US |
dc.subject | Turkey | en_US |
dc.title | Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 41 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 597 | en_US |
dc.identifier.endpage | 607 | en_US |
dc.identifier.doi | 10.1007/s10096-021-04394-0 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 6603843040 | - |
dc.authorscopusid | 6506439433 | - |
dc.authorscopusid | 12783463800 | - |
dc.authorscopusid | 56313019000 | - |
dc.authorscopusid | 55664567200 | - |
dc.authorscopusid | 21743795100 | - |
dc.authorscopusid | 36116637700 | - |
dc.identifier.pmid | 35083558 | en_US |
dc.identifier.scopus | 2-s2.0-85123593534 | en_US |
dc.identifier.wos | WOS:000749138700001 | en_US |
dc.identifier.scopusquality | Q1 | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
12
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
12
checked on Oct 31, 2024
Page view(s)
66
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.